Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates as the loss of patent exclusivity on diabetes drug Januvia and other medicines will hit harder than analysts are projecting.
Merck Forecasts 2026 Sales Below Estimates On Patent Losses
About the Author: ryounglao
Leave A Comment